US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CAR-T Concept

1,717.76

-1.2598-0.07%

Number of Gainers:1

Number of Losers:1

Number of Flat:- -

PE:- -

High:1,730.47

Open:1,728.65

Low:1,716.32

Close:1,719.02

Volume:1.74M

Turnover:246.06M

Market Cap:442.73B

Float Cap:434.48B

Loading ...

Novartis India - Deal Valued at 12.50 Bln Rupees

THOMSON REUTERS

Novartis Shares to Take Hit from Cholesterol Trial Failure

Dow Jones Top Company Headlines at 9 PM ET: Amazon Cargo Plane Overshoots Runway in Miami, Killing Five People | Carmakers ...

Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal

Stocks to Watch: Ionis Pharmaceuticals, Novartis, Corvex

Novartis Pelacarsen Fails Phase III Cardiovascular Outcomes Trial

MT Newswires Live

Novartis announces Phase 3 pelacarsen study did not meet primary endpoint

Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint

Novartis AG Falls Friday, Underperforms Market

Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects

Dow Jones Top Company Headlines at 11 PM ET: the 'Deeply Nerdy' Founders Behind Nvidia's $13 Billion Bet on Hugging Face | Musk's ...

Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Gilead CEO Daniel O'Day Disposes of USD 2.23 Million in Common Shares

H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme

Novartis AG Rises Wednesday, Outperforms Market

Novartis, Alteogen Sign Drug-Technology Deal Worth Up to $3.2 Billion

MT Newswires Live

Is Gilead Sciences (GILD) Fully Valued On Its New HIV And Cancer Drug Approvals?

Simply Wall St.

Alteogen enters option, license agreement with Novartis

Novartis Trial Suspensions to Have Limited Financial Impact

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/BK4578/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1717.7645,"timestamp":1789052680474,"preClose":1719.0243,"halted":0,"volume":1743815,"delay":0,"changeRate":-0.000733,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-1.259766,"latestTime":"09-10 11:04:42 EDT","open":1728.6481,"high":1730.4697,"low":1716.3235,"amount":246058737.32512,"amplitude":0.008229,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":8.314749,"peRate":46.628821,"turnoverRate":0.000564,"increases":1,"decrements":1,"flats":0,"marketCap":442730299392,"floatMarketCap":434476695552},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1730.4697,"amplitude":0.008229,"preClose":1719.0243,"low":1716.3235,"pbRate":"8.314749","latestPrice":1717.7645,"volume":1743678,"delay":0,"open":1728.6481,"prevYearClose":1612.5378,"prevWeekClose":1911.2454,"prevMonthClose":1830.2803,"prevQuarterClose":1768.1697,"fiveDayClose":1922.4193,"twentyDayClose":1781.5829,"sixtyDayClose":1720.4836,"secType":"PLATE","market":"US","turnoverRate":0.000564,"peRate":46.628821,"marketCap":442730299392,"floatMarketCap":434476695552,"timestamp":1789052678929,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":1,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665391143","title":"Novartis India - Deal Valued at 12.50 Bln Rupees","url":"https://stock-news.laohu8.com/highlight/detail?id=2665391143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665391143?lang=en_us&edition=fundamental","pubTime":"2026-09-07 13:56","pubTimestamp":1788760577,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nFWN44Y00E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","IE00B2B36J28.USD","LU0320765489.SGD","BK4588","NVS","MEDX","LU0211331839.USD","BK4532","BK4578","PPH","IE00BJJMRZ35.SGD","LU0208291251.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0070302665.USD","BK4007","IE0002141913.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665684391","title":"Novartis Shares to Take Hit from Cholesterol Trial Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2665684391","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665684391?lang=en_us&edition=fundamental","pubTime":"2026-09-07 13:43","pubTimestamp":1788759780,"startTime":"0","endTime":"0","summary":"0543 GMT - Novartis shares are likely to take a hit from news that a cholesterol drug candidate failed to reduce the risk of severe cardiovascular events like heart attacks and strokes in a late-stage trial, J.P. Morgan analysts say in a research note. Consensus estimates for Novartis included $1 billion in 2030 sales from the drug, called pelacarsen, the analysts say. Shares in the Swiss drugmaker are likely to be off 2% to 3% on Monday as a result, they add. Upcoming trial results for del-desiran, an experimental treatment for genetic neuromuscular disorder myotonic dystrophy type 1, are likely to be positive and could allow Novartis to more than erase stock weakness caused by the pelacarsen results, according to JPM.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Novartis Shares to Take Hit from Cholesterol Trial Failure","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211331839.USD","BK4588","NVS","BK4007","PPH","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0070302665.USD","MEDX","IE00B2B36J28.USD","LU0208291251.USD","IE00B4R5TH58.HKD","IE0009355771.USD","IE0002141913.USD","BK4585","BK4532","BK4578","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398915","title":"Dow Jones Top Company Headlines at 9 PM ET: Amazon Cargo Plane Overshoots Runway in Miami, Killing Five People | Carmakers ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398915","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665398915?lang=en_us&edition=fundamental","pubTime":"2026-09-07 09:00","pubTimestamp":1788742800,"startTime":"0","endTime":"0","summary":"Amazon Cargo Plane Overshoots Runway in Miami, Killing Five PeopleMore than 60 Miami-Dade Fire Rescue units rushed to the scene to put out the flames and assess any injuries.----Carmakers Have a New I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1BXHZ80.USD","IE0009G5SDU7.USD","LU0942090050.USD","IE00B5949003.HKD","TSLI","LU0345770993.USD","LU1145028129.USD","LU0868494617.USD","LU1267930813.SGD","AMZO","LU2362541513.USD","SG9999004303.SGD","LU0208291251.USD","SGXZ51526630.SGD","LU2461242641.AUD","LU2756315318.SGD","TSLZ","LU2505996681.GBP","IE00BQXX3C00.GBP","LU0061475181.USD","IE00BMPRXQ63.HKD","ADBE","BK4532","SG9999015978.USD","LU1861559042.SGD","LU0053666078.USD","LU0238689110.USD","LU0494093205.USD","LU1814569148.SGD","LU2077746001.SGD","LU2750360997.AUD","LU2168564149.EUR","LU2087625088.SGD","LU2242649171.HKD","BK4158","BK4516","IE00BFXG0V08.USD","LU0276348264.USD","LU0965509283.SGD","IE0009356076.USD","LU0211331839.USD","LU2756315664.SGD","IE00B5TLWC47.USD","LU0708994859.HKD","LU0069063385.USD","BK4574","LU2087621335.USD","LU0528227936.USD","LU0170899867.USD","BK4535","TSLG","IE00B3SWFQ91.USD","LU2954938101.SGD","BK4579","LU0871640123.AUD","FRNW","CLIX","LU1791710582.SGD","LU1880398554.USD","LU2023250843.SGD","LU1691799644.USD","LU2471134879.HKD","LU0306807586.USD","AMZG","LU0211327993.USD","LU2462591350.SGD","VCLN","IE000F7OJYX1.SGD","IE00B3S45H60.SGD","LU1244550221.USD","LU1435385759.SGD","BLDR","LU0289960550.SGD","TSLP","LU1868837300.USD","IE0000B7K699.USD","LU1623119135.USD","SGXZ44715902.SGD","BK4503","ILDR","LU2065171402.SGD","LU0949170426.SGD","LU1267930730.SGD","LU2750360641.GBP","LU0198837287.USD","IE000ITXATA3.USD","LU0784384876.USD","RTH","LU1989764664.SGD","LU0882574139.USD","IE00BJT1NW94.SGD","LU0823434583.USD","AMZY","WATS","IE000BZT7R73.USD","BK4613","LU1119994496.HKD","LU2896262040.SGD","BK4533","LU0417517546.SGD","LU2543165471.USD","LU0082616367.USD","LU1880398471.USD","LU2417539215.USD","HULL","LU1066051498.USD","LU0149725797.USD","LU2095319765.USD","LU2764262908.HKD","SGXZ99366536.SGD","SMOG","LU0784385170.HKD","IE00B7SZLL34.SGD","LU0158827781.USD","IE0009355771.USD","LU1861127337.USD","LU2028103732.USD","LU1153585028.USD","LU2290526834.HKD","LU1244550494.USD","LU0106261372.USD","LU1861220033.SGD","LU0289739343.SGD","TSLW","LU0345770308.USD","EGGY","LU2249611893.SGD","BK4604","IE000WAW04H5.SGD","BK4009","LU1316542783.SGD","LU0823411888.USD","LU1674673691.USD","LU0072461881.USD","IE000M9KFDE8.USD","LU0672654240.SGD","SG9999014898.SGD","LU0820561909.HKD","IE00B19Z8X17.USD","LU1935043023.USD","LU2237957811.SGD","TSDD","BK4550","LU0823414551.USD","LU1720051108.HKD","IE0034235303.USD","LU0444973449.USD","IE0005OL40V9.USD","SG9999001077.SGD","IE000MB6IJN5.SGD","LU0353189680.USD","LU0965508806.USD","IE0004445239.USD","LU0354030511.USD","SGXZ80539844.SGD","LU2210150020.SGD","LU2168564065.EUR","LU2361044865.SGD","IE0002270589.USD","CRSH","IE00BJLML261.HKD","LU2271345857.HKD","IE0004091025.USD","LU0788109477.HKD","LU0868494708.USD","LU1815336760.USD","LU0107464264.USD","LU1823568750.SGD","IE00BKVL7J92.USD","BK4543","TSLL","LU0174119429.USD","LU1935043452.HKD","LU0081259029.USD","09766","LU0210528500.USD","STLA","LU1868837136.USD","LU0985320562.USD","TTDU","SG9999000418.SGD","LU1674673428.USD","VTWG","LU0056508442.USD","LU0251132253.USD","BK4086","LU2362540622.SGD","LU2250418816.HKD","ADBU","LU2023251221.USD","LU0154236417.USD","LU0640476718.USD","LU0786609619.USD","LU1261432733.SGD","LU0096364046.USD","LU1868836591.USD","LU2746668974.SGD","LU0109392836.USD","IE00B19Z9505.USD","LU0203202063.USD","LU0823414478.USD","IE00BSNM7G36.USD","IE00BJTD4V19.USD","LU2275660780.HKD","IE00BFTCPJ56.SGD","SG9999018865.SGD","LU2317271919.USD","LU0889565833.HKD","LU0683600562.USD","GB00BDT5M118.USD","LU0130103400.USD","IBAT","BK4596","HYDR","LU1074936037.SGD","IE00BJJMRX11.SGD","LU2083900584.USD","CTEC","LU2237957902.USD","LU1935042488.USD","LU0158827948.USD","LU2168563687.JPY","LU2430703095.HKD","UPGR","LU0256863811.USD","LU1935043536.SGD","LU2210149790.SGD","IE00BQXX3D17.EUR","LU2602419157.SGD","LU0267386448.USD","LU2357305700.SGD","LU2063271972.USD","LIT","IE00B1XK9C88.USD","IE000W1ABFV2.USD","BK4555","LU0265550359.USD","IDRV","IE00BN29S564.USD","LU0321505439.SGD","IE00B19Z3B42.SGD","LU1116320737.USD","TSLS","BK4551","LU0127658192.USD","LU0079474960.USD","LU2746668461.USD","ADBG","LU2456880835.USD","LU0314104364.USD","LU0648001328.SGD","LU0070217475.USD","LU2505996509.AUD","BK4541","LU2471134952.CNY","LU0130102774.USD","LU0162691827.USD","LU2237438978.USD","SAMZNmain","LU0820562030.AUD","LU1235294995.USD","IE00BK4W5L77.USD","LU0472753341.HKD","LU2463028550.USD","AMZW","LU0957808578.USD","LU1066051811.HKD","LU1244550577.SGD","LU2360106780.USD","LU2125154935.USD","LU0070302665.USD","BK4220","LU0320765059.SGD","LU1069344957.HKD","BK4559","LU0096362180.USD","LU1934455863.HKD","IE00BMPRXN33.USD","LU0109391861.USD","CNRG","BK4566","LU0251142724.SGD","LU0225771236.USD","LU1201861249.SGD","LU1815333072.USD","LU0321505868.SGD","LU1301847155.USD","LU2720916845.USD","LU0823421416.USD","AMAA","LU2361045086.USD","TSYY","AMZZ","AZYY","LU1037948897.HKD","LU2089284900.SGD","TLA","BEG","LU0310800379.SGD","LU0784385840.USD","HK0000914660.USD","LU1429558221.USD","IE00B19Z8W00.USD","LU2092627202.USD","LU2458330243.SGD","LU1496350502.SGD","LU2420271590.USD","SG9999015945.SGD","LU0345768153.USD","F","BE","IE00BFSS7M15.SGD","LU0097036916.USD","LU0006306889.USD","PPH","LU0048573561.USD","HK0000532082.HKD","LU0345774631.USD","BK4561","LU2487616109.SGD","IE00B775H168.HKD","LU0708995401.HKD","AMZN","BK4534","LU0348723411.USD","LU1035775433.USD","LU1366333091.USD","SG9999014906.USD","BK4578","TESC","LU0308772762.SGD","LU2213496289.HKD","LU2506951792.HKD","IE000SO60NU8.SGD","LU1791710400.SGD","BEC","BK4099","LU0557290698.USD","LU0719512351.SGD","IE00BZ1G4Q59.USD","LU1267930573.SGD","LU0390134368.USD","IE00BFSS8Q28.SGD","LU0316494557.USD","LU2023250504.SGD","BK4023","LU0466842654.USD","LU1548497426.USD","LU0823434740.USD","LU2552382132.HKD","LU0345768740.USD","LU2362541273.HKD","LU1066053197.SGD","LU0648000940.SGD","LU1064131342.USD","LU1551013425.SGD","LU1642822529.SGD","IE00BJJMRY28.SGD","SG9999014914.USD","LU0511384066.AUD","AMZD","LU1988902786.USD","LU0210533765.USD","LU1778281490.HKD","LU1804176565.USD","LU0133085943.USD","LU1267930490.SGD","AMZU","TSLQ","ICLN","IE00BKDWB100.SGD","IE00BJTD4N35.SGD","LU2247934214.USD","LU1323610961.USD","LU0345774391.USD","LU0889566641.SGD","IE0004086264.USD","ZAP","ONLN","LU1883839398.USD","LU1974910355.USD","IE000YTNTUN2.SGD","LU0234570918.USD","LU0310799852.SGD","LU2168564222.USD","LU2361044949.HKD","LU0306806265.USD","LU1861215975.USD","LU1084165304.USD","LU1935042215.USD","IE0003U64NQ7.SGD","SG9999001424.SGD","BK4182","LU1935042991.SGD","TSLT","HK0000304797.USD","LU2089283258.USD","BK4585","LU2462157665.USD","LU0345769128.USD","LU0354030438.USD","IE0001KFT4U8.USD","LU0210536198.USD","LU1046421795.USD","LU0312595415.SGD","LU2065171311.SGD","BK4524","SG9999015952.SGD","LU0689472784.USD","SGXZ81514606.USD","LU2023250330.USD","BK4511","IE0002141913.USD","BEX","LU1839511570.USD","09366","LU2430703178.SGD","BK4528","LU1852331112.SGD","BK4007","LU2092937148.SGD","07366","LU1127390331.HKD","BK4527","LU1633808545.USD","LU1861558580.USD","LU1718418525.SGD","IE00BWXC8680.SGD","BK4612","LU2108987350.USD","LU0225284248.USD","LU1629891620.HKD","LU1989764748.USD","SG9999015986.USD","XHB","TSII","LU0345769631.USD","LU2764263039.SGD","LU2458330169.SGD","IE00BK4W5M84.HKD","LU2211817866.USD","LU1116320901.HKD","BK4581","NVS","LU1232071149.USD","BEZ","BK4598","LU1066051225.USD","LU0965509101.SGD","LU0323591593.USD","LU2637965513.SGD","LU2360032135.SGD","LU0080751232.USD","LU1496350171.SGD","LU2097829019.USD","IE00BJJMRZ35.SGD","LU2471134523.USD","ELOL","LU2294711713.HKD","USAW.SI","LU0742534661.SGD","LU1803068979.SGD","LU2265009873.SGD","LU0289961442.SGD","LU2054465674.USD","LU2360107168.USD","SG9999018857.SGD","LU1280957306.USD","HK0000914686.HKD","LU0861579265.USD","LU0784383803.USD","TTD","BK4567","LU2592432038.USD","LU0175139822.USD","SGXZ23171101.USD","SG9999017495.SGD","TSLR","LU1934455277.USD","LU0251131958.USD","LU1551013342.USD","LU0476273544.USD","IE00B4YYXB79.USD","LU0820561818.USD","LU0724617625.USD","SIMS","LU1914381329.SGD","IE00B4R5TH58.HKD","LU1868836914.USD","LU1868836757.USD","STSLAmain","LU0256863902.USD","TSLO","MEDX","LU0342679015.USD","LU0456855351.SGD","LU0234572021.USD","LU0061474960.USD","LU0302445910.USD","BK4554","IE00BYQQ9H92.USD","LU0072462426.USD","LU0215105999.USD","OGIG","SG9999002224.SGD","TSLA","IE00B2B36J28.USD","LU0980610538.SGD","LU1064927863.SGD","LU0203201768.USD","LU0138981039.USD","LU2111349929.HKD","LU2999663052.SGD","BK4592","TSL","LU2264538146.SGD","LU1979441026.SGD","LU0965509010.AUD","WANT","LU2242650005.HKD","LU2065169927.USD","TESL","LU0823421333.USD","IE00BKPKM429.USD","IE00BQXX3F31.USD","LU0444971666.USD","LU0943347566.SGD","LU0057025933.USD","LU2381873111.SGD","LU0353189763.USD","BK4538","SG9999002232.USD","LU0964807845.USD","IE00B775SV38.USD","LU2065170008.USD","IE0009354923.USD","SG9999014880.SGD","LU2764263203.CNY","LU2403377893.USD","HK0000304805.HKD","LU1037948541.HKD","LU0061474705.USD","LU1720051017.SGD","IE00BMPRXR70.SGD","IE00B7KXQ091.USD","LU0787776722.HKD","FRDD","BK4507","IE00B19Z3581.USD","07766","LU0077335932.USD","LU0048584097.USD","LU1201861165.SGD","LU2236285917.USD","LU0157215616.USD","LU2168564495.EUR","FDRV","LU2860962120.EUR","LU0985481810.HKD","LU2452424414.USD","AMZP","LU0289941410.SGD","LU0128525929.USD","LU2326559502.SGD","BK4122","LU0265550946.USD","LU0792757196.USD","LU2552382215.SGD","IE00B3T34201.USD","TAP","TEST","FRDU","LU0211328371.USD","LU0029864427.USD","LU2462591277.SGD","LU2471134796.USD","LU2125154778.USD","LU0957791311.USD","TSLY","LU0642271901.SGD","LU1934455194.USD","IE00B4JS1V06.HKD","LU2357125470.USD","LU0011850046.USD","LU1712237335.SGD","LU2211815571.USD","BK4548","BK4588","IE000KEQY171.SGD","LU0320765489.SGD","LU1917777945.USD","LU2106854487.HKD","IE0004445015.USD","LU0143551892.USD","LU2430703251.USD","LU1366192091.USD","LU2552382058.USD","SGXZ31699556.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665524173","title":"Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2665524173","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665524173?lang=en_us&edition=fundamental","pubTime":"2026-09-05 07:55","pubTimestamp":1788566100,"startTime":"0","endTime":"0","summary":"A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study, dealing a blow to the company and others exploring a new approach to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","PPH","LU0211331839.USD","LU0208291251.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","NVS","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4532","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4585","LU0320765489.SGD","BK4007","BK4588","MEDX","LU0070302665.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665352693","title":"Stocks to Watch: Ionis Pharmaceuticals, Novartis, Corvex","url":"https://stock-news.laohu8.com/highlight/detail?id=2665352693","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665352693?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:58","pubTimestamp":1788562680,"startTime":"0","endTime":"0","summary":"A heart disease drug made by Ionis Pharmaceuticals and Novartis didn't meet its primary endpoint in a Phase 3 trial. Ionis shares slid 9.5% to $52.60 in after-hours trading on Friday, while Novartis shares were off 4.4% at $153.04.Corvex said it had a loss of $26.3 million in the first half of the year. The stock fell 7.5% to $13.63 after the bell.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765489.SGD","MEDX","BK4578","IE00B4R5TH58.HKD","NVS","LU0211331839.USD","IONS","LU0070302665.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","BK4007","IE00B2B36J28.USD","MOVE","BK4588","IE0009355771.USD","PPH","BK4139","BK4532","BK4170","BK4585","IE00BJT1NW94.SGD","IE0002141913.USD","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354352","title":"Novartis Pelacarsen Fails Phase III Cardiovascular Outcomes Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354352","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354352?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:36","pubTimestamp":1788561414,"startTime":"0","endTime":"0","summary":"Novartis AG (NVS) said Friday its Phase III Lp(a)HORIZON trial of pelacarsen did not meet its primary endpoint of reducing the risk of cardiovascular events compared with placebo.The primary endpoint ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0009355771.USD","BK4585","BK4532","IE00B4R5TH58.HKD","MEDX","BK4082","BK4588","IE00B2B36J28.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","LU0208291251.USD","BK4578","PPH","LU0211331839.USD","IE00BJT1NW94.SGD","CSII","NVS","LU0070302665.USD","IE00BJJMRZ35.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665535175","title":"Novartis announces Phase 3 pelacarsen study did not meet primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2665535175","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665535175?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:55","pubTimestamp":1788555312,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals (IONS) partner Novartis (NVS) announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-announces-phase-3-pelacarsen-study-did-not-meet-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-announces-phase-3-pelacarsen-study-did-not-meet-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IE0009355771.USD","BK4585","BK4532","IE00B4R5TH58.HKD","MEDX","BK4588","IE00B2B36J28.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","LU0208291251.USD","IONS","BK4578","PPH","LU0211331839.USD","IE00BJT1NW94.SGD","NVS","LU0070302665.USD","IE00BJJMRZ35.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665235141","title":"Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2665235141","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665235141?lang=en_us&edition=fundamental","pubTime":"2026-09-05 04:50","pubTimestamp":1788555000,"startTime":"0","endTime":"0","summary":"Novartis said a heart disease drug did not meet its primary endpoint in a Phase 3 study.The company on Friday said that the drug, pelacarsen, did not reduce the risk of cardiovascular events--including deaths, heart attacks, and strokes--compared to a placebo.The drug did succeed in lowering lipoprotein levels, Novartis said.\"These are not the results we hoped for, but they provide important evidence that advances scientific understanding of the relationship between Lp lowering and cardiovascular outcomes and may help inform future approaches to cardiovascular risk management,\" Chief Medical Officer Shreeram Aradhye said.Pelacarsen was initially discovered and developed by Ionis Pharmaceuticals, before Novartis exercised an option to license development and commercialization rights for the drug in 2019.Shares of Novartis declined 4.4% to $153.00 in after-hours trading on Friday. Ionis shares were flat.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0320765489.SGD","IE0002141913.USD","BK4578","IE0009355771.USD","LU0208291251.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","BK4588","IE00BJT1NW94.SGD","NVS","IE00B4R5TH58.HKD","IONS","BK4532","LU0070302665.USD","BK4007","BK4585","MEDX","PPH","IE00B2B36J28.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665635396","title":"Novartis AG Falls Friday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2665635396","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665635396?lang=en_us&edition=fundamental","pubTime":"2026-09-05 00:15","pubTimestamp":1788538500,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novartis AG  dropped 1.3% to CHF129.58 Friday on what proved to be an overall mediocre trading session for the stock market, with the Swiss Market Index SMI Index  holding steady at 14,395.94.Novartis AG closed CHF3.10 short of its 52-week high of CHF132.68, which the company achieved on September 3, 2026.Trading volume was 2,616,060, compared to the 50-day average trading volume of 2,312,024.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","PPH","MEDX","IE00BJT1NW94.SGD","BK4585","IE0002141913.USD","LU0211331839.USD","IE00BFTCPJ56.SGD","LU0208291251.USD","BK4532","BK4588","LU0070302665.USD","NVS","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4007","BK4578","LU0320765489.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664375653","title":"Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2664375653","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664375653?lang=en_us&edition=fundamental","pubTime":"2026-09-04 21:42","pubTimestamp":1788529320,"startTime":"0","endTime":"0","summary":"Bristol Myers Squibb told regulators, researchers and patient-advocacy groups in early June that it had paused closely watched drug research because of life-threatening side effects. It took three mon","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096364046.USD","IE0002141913.USD","LU0985481810.HKD","LU1883839398.USD","IE0009355771.USD","LU0882574055.USD","LU1670710661.SGD","LU0267386448.USD","FTXH","LU1291159041.SGD","IHE","LU1430594728.SGD","IE00BFXG1179.USD","IE00BSNM7G36.USD","LU0114720955.EUR","LU1670710588.SGD","LU1989771016.USD","LU0321505439.SGD","LU0306806265.USD","LU0868494617.USD","BK4559","IE00BJJMRZ35.SGD","LU0320765489.SGD","LU1585245621.USD","LU2242646821.SGD","NVS","MEDX","LU1236620834.HKD","IE00BJT1NW94.SGD","LU0225771236.USD","LU1983299246.USD","LU2360032135.SGD","PPH","LU1670711040.USD","LU2133065610.SGD","LU1093756325.SGD","LU1868836757.USD","BK4578","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0306807586.USD","BK4532","LU0321505868.SGD","LU1670711123.USD","LU2596442595.SGD","LU1571399168.USD","BK4534","LU0070302665.USD","LU0061475181.USD","BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385954","title":"Dow Jones Top Company Headlines at 11 PM ET: the 'Deeply Nerdy' Founders Behind Nvidia's $13 Billion Bet on Hugging Face | Musk's ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385954","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664385954?lang=en_us&edition=fundamental","pubTime":"2026-09-04 11:00","pubTimestamp":1788490800,"startTime":"0","endTime":"0","summary":"The 'Deeply Nerdy' Founders Behind Nvidia's $13 Billion Bet on Hugging FaceThe startup began as an emoji-named app for teens before becoming a crusader for open-source artificial intelligence.----Musk","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0683600562.USD","LU2247934214.USD","LU1037948897.HKD","LU2047632596.USD","LU0274383776.USD","IE00BZ1G4Q59.USD","LU0345769631.USD","LU0494093205.USD","LU0158827781.USD","LU2125909916.SGD","LU2063271972.USD","BK4554","IE000YTNTUN2.SGD","LU2552382058.USD","GAMR","TSLI","2NVD.UK","LU2211815571.USD","SG9999015341.SGD","LU2430703095.HKD","IE00BWXC8680.SGD","LU2458330169.SGD","HK0000320223.HKD","LU2286300806.USD","LU0719512351.SGD","LU0127658192.USD","SG9999014567.USD","LU0158827948.USD","LU0708995401.HKD","FDRV","LU2413666699.HKD","LU1868837300.USD","BK4559","LU1989772923.USD","LU2111349929.HKD","LU1821325948.USD","BK4023","IE00BJTD4N35.SGD","LU1236620834.HKD","LU1003077747.HKD","LU1244550221.USD","LU2433249047.HKD","IE00BJLML261.HKD","LU0788109477.HKD","LU0081259029.USD","CRSH","LU2317271919.USD","LU2491050071.SGD","LU0316494557.USD","HK0000304797.USD","LU0979878070.USD","LU1116320737.USD","AIPI","LU1571399168.USD","LU1235294995.USD","LU1429558221.USD","BK4202","LU0029864427.USD","LU1551013425.SGD","ROM","LU0211328371.USD","SG9999015978.USD","LU2272731865.HKD","LU2168564495.EUR","SG9999004303.SGD","LU0069063385.USD","LU3102509885.SGD","BK4604","IE00BJJMRY28.SGD","LU0345770993.USD","LU2954938101.SGD","LU2083900584.USD","NVDA","NVDU","LU1883839398.USD","LU2543165471.USD","LU0321505868.SGD","LU1585245621.USD","LU0795875086.SGD","LU1267930490.SGD","LU1934455194.USD","LU0170899867.USD","SMOG","LU1242518931.SGD","CLSE","IE00BQXX3C00.GBP","NVDS.UK","LU0006306889.USD","LU1988902786.USD","LU2347655073.USD","NVDL","ABFL","LU1989764664.SGD","LU1144417596.USD","LU2092937148.SGD","LU0234572021.USD","BK4614","SGXZ51526630.SGD","LU2294711713.HKD","NVD3.UK","LU0251132253.USD","LU0943347566.SGD","LU1435385759.SGD","LU0048584097.USD","LU0889565833.HKD","LU2089284900.SGD","LU2023250330.USD","LU1732800096.USD","LU2028103732.USD","LU2250418816.HKD","HK0000320264.USD","IE00BFSS8Q28.SGD","LU1712237335.SGD","BK4574","LULG","LU1244550494.USD","LU0082616367.USD","LU2089283258.USD","LU2471134523.USD","IE00BMPRXN33.USD","IE0034235295.USD","LU1868836591.USD","LU0557290698.USD","LU2023251221.USD","IE00BDCRKT87.USD","IE00BZ199S13.USD","LU2326559502.SGD","LFGY","LU1046421795.USD","LU1868837136.USD","LU1280957306.USD","LU0211327993.USD","SG9999002232.USD","SG9999001424.SGD","LU0964807845.USD","LU2456880835.USD","LU0345774391.USD","VT","LU2552382132.HKD","IE00BN29S564.USD","LU2361044949.HKD","LU2430703178.SGD","LU2065169927.USD","LU0823434740.USD","FDTX","BK4550","LU1868836914.USD","LU0511384066.AUD","LU1074936037.SGD","LU1992135399.USD","LU2271345857.HKD","LU2125154778.USD","ESUM","LU2237443978.SGD","LU1261432733.SGD","SG9999015358.SGD","HK0000532082.HKD","TSLQ","LU2092627202.USD","LU0345768740.USD","LU2505996681.GBP","SOXQ","LU0985481810.HKD","BK4581","LU0432979614.USD","LU0957791311.USD","LU0234570918.USD","LU2087621335.USD","LU0154236417.USD","IE00BQXX3F31.USD","LU1861559042.SGD","LU1951200564.SGD","LU0642271901.SGD","FAI","LU0889566641.SGD","NULC","TSLA","LU2471134879.HKD","LU0323591593.USD","LU1629891620.HKD","BK4097","LU2168564222.USD","SG9999014880.SGD","IE00BKVL7J92.USD","LU0868494708.USD","LU1366333091.USD","LU2237443465.HKD","NVD2.UK","IDRV","LU2491049909.HKD","07766","SPTE","LU2361045086.USD","LU2637965513.SGD","LU1064131342.USD","BK4551","BK4549","LU2095319765.USD","LU2360107168.USD","IE0009356076.USD","HK0000914686.HKD","LU0225284248.USD","LU1202635105.USD","LU1496350171.SGD","IE0004445015.USD","LU2452424414.USD","LU0289739343.SGD","LU0823421416.USD","LU1232071149.USD","LU1861558580.USD","LU2237443549.SGD","LU0823411888.USD","LU2191332357.HKD","IXN","LU1400636574.HKD","HK0000914660.USD","LU2133065610.SGD","LU2249611893.SGD","LU0133085943.USD","LU0444973449.USD","LU2999663052.SGD","LU1032466523.USD","LU2430703251.USD","LU2237438978.USD","LU2746668974.SGD","VGT","BK4560","LU0724617625.USD","LU0354030511.USD","LU0208291251.USD","LU2125909247.SGD","SG9999014898.SGD","LU2347655156.SGD","DIPS","LU0070217475.USD","LU2236285917.USD","LU1400636491.USD","IE00BHPRN162.USD","LU1430594728.SGD","LU0011850046.USD","NVYY","IE0005OL40V9.USD","IE000ITXATA3.USD","BK4007","LU0070302665.USD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","LU2381873111.SGD","LU0689472784.USD","LU1267930573.SGD","LU2746668461.USD","LU2168564065.EUR","LU2471134952.CNY","LU1814569148.SGD","TSII","IETC","IE0034235188.USD","IE00B775H168.HKD","LU1934455863.HKD","LU2065171402.SGD","SG9999018865.SGD","BK4099","LU2237443895.HKD","LU2750360641.GBP","LU1721428933.USD","LU0174119429.USD","LU2602419157.SGD","CNEQ","LU2213496289.HKD","SG9999000418.SGD","09788","LU0266013472.USD","LU1645745479.HKD","LU1983299246.USD","LU0320765489.SGD","LU2552382215.SGD","LU1868836757.USD","LU2322448791.USD","LU1116320901.HKD","LU1718418525.SGD","LU1720051017.SGD","07388","LU1914381329.SGD","LU2458330243.SGD","LU0109392836.USD","IHE","SMHX","BK4527","GB00BDT5M118.USD","LU1804176565.USD","LU2264538146.SGD","LU0323239441.USD","CMAG","LU2596442595.SGD","LU2077746001.SGD","LU0096364046.USD","LU2210149790.SGD","TSN","SNVDAmain","LU0949170772.SGD","LU1861215975.USD","LU0308772762.SGD","LU0276348264.USD","ADBE","BK4212","LU2279689827.SGD","TSLR","LU2097344357.USD","LU1400636657.SGD","LU0823414478.USD","LU2108987350.USD","BK4529","LU1815333072.USD","LU0306807586.USD","FTXH","HK0000306685.HKD","IE00B2B36J28.USD","TSLL","IE0004086264.USD","LU1066051811.HKD","SG9999017495.SGD","LU2361044865.SGD","BK4608","LU1153585028.USD","IE00B19Z9505.USD","IE00B19Z8W00.USD","ZS","LU0210536198.USD","BK4504","TEK","LU0157215616.USD","LU2357125470.USD","LU0965509010.AUD","TEST","HK0000306701.USD","LU1066051225.USD","LU1923623000.USD","LU1267930813.SGD","FTEC","IE00BK4W5L77.USD","LU1983260115.SGD","LU2242649171.HKD","USXF","XLK","LU0472753341.HKD","LU1127390331.HKD","LU2931357623.SGD","SNPE","BK4503","LU0545039389.USD","LU2242652126.USD","LU2272731782.SGD","LU1670756490.USD","LU1674673691.USD","LU0056508442.USD","LU1069344957.HKD","LU2750360997.AUD","BK4585","LU1992135472.HKD","LU0225283273.USD","IE00BMPRXQ63.HKD","LU0238689110.USD","LU0823434583.USD","LU0861579265.USD","LU1974910355.USD","TESC","IE00B3SWFQ91.USD","SG9999015986.USD","LU1035775433.USD","LU1236620750.USD","LU2097344431.USD","AGOX","LU0061475181.USD","LU0310800379.SGD","LU2168563687.JPY","SG9999014906.USD","LU2462157665.USD","LU0143551892.USD","LU0175139822.USD","SHOC","LU0395794307.EUR","LU0672654240.SGD","LU2491050154.USD","LU2360032135.SGD","SG9999014914.USD","LU1852331112.SGD","LU0314104364.USD","LU0128525929.USD","BK4567","LU1861127337.USD","LU2487616109.SGD","TSLW","LU2471134796.USD","ILDR","BK4579","IE00B5949003.HKD","LU1670711123.USD","LU2462591277.SGD","LU0321505439.SGD","LU1069347547.HKD","LU2242650005.HKD","LU2420271590.USD","IE0009G5SDU7.USD","LU0345774631.USD","IE00BYXW3230.USD","NVDS","LU2148611432.USD","IE00BJTD4V19.USD","LU2403377893.USD","TTEQ","LU0528227936.USD","LU0077335932.USD","LU2461242641.AUD","BK4598","IE00BDRTCR15.USD","3NVD.UK","LU1778281490.HKD","LU2237443382.USD","LU2125154935.USD","LIT","LU1633808545.USD","IE00BKDWB100.SGD","LU1720051108.HKD","NVDO","NVDX","LU2413666426.HKD","NVDG","LU0203202063.USD","LU0738911758.USD","LULU","IE0003U64NQ7.SGD","BK4566","LU1674673428.USD","BK4605","LU1093756168.USD","TSLS","CHPX","IE00B3M56506.USD","STSLAmain","LU2860962120.EUR","LU2506951792.HKD","LU1496350502.SGD","LU0079474960.USD","ESLG","CPB","IE00B5TLWC47.USD","TLA","LU1145028129.USD","NVDW","LU1093756325.SGD","IE00B1XK9C88.USD","BK4534","IE00B1BXHZ80.USD","IE00BK4W5M84.HKD","IE00BKPKM429.USD","IE00BFSS7M15.SGD","SOXY","TRFK","BK4543","LU0345768153.USD","LU0210528500.USD","IE0004445239.USD","ELOL","SOXX","LU0114720955.EUR","LU0553294199.USD","LU1084165304.USD","LU0882574055.USD","LU2505996509.AUD","IE00BD6J9T35.USD","IE00B4R5TH58.HKD","LU1691799644.USD","IE00BFXG1179.USD","LU0965509283.SGD","IE00BQXX3D17.EUR","LU1119994496.HKD","LU1037948541.HKD","LU1934455277.USD","09766","LU0061474705.USD","LU0097036916.USD","LU1066051498.USD","SG9999014542.SGD","LU1935042991.SGD","IE00BFTCPJ56.SGD","LU0265550359.USD","LU1839511570.USD","LU0320765059.SGD","NVDQ","LU0708994859.HKD","PPH","SGXZ31699556.SGD","LU0726765562.USD","LU0109391861.USD","LU0820562030.AUD","LU1880398554.USD","BK4516","LU0957808578.USD","SG9999014575.USD","LU2087625088.SGD","MEDX","NVDB","LU0985320562.USD","SG9999015945.SGD","LU0124676726.USD","LU2100268510.USD","IE00B775SV38.USD","LU2417539215.USD","LU1623119135.USD","SMH","TSL","LU0353189763.USD","LU0689626769.HKD","LU1935043023.USD","LU0267386448.USD","IE00BJJMRX11.SGD","LU2756315318.SGD","LU0210533765.USD","LU2106854487.HKD","THMR","TSLP","LU2125909593.SGD","METV","LU1035773651.USD","NVD","LU0198837287.USD","NVS","LU0211331839.USD","LU0820561818.USD","LU0094547139.USD","LU0057025933.USD","LU1291159041.SGD","BK4548","LU1366192091.USD","LU2065171311.SGD","LU1935042215.USD","IE00B4JS1V06.HKD","LU2168564149.EUR","LU0265550946.USD","ANV","LU1791710582.SGD","LU1861220033.SGD","TSLY","LU1917777945.USD","LU2054465674.USD","SGXZ80539844.SGD","LU0444971666.USD","TYLG","LU2592432038.USD","LU1066053197.SGD","IE000Q6AESB8.SGD","LU0096362180.USD","LU0456855351.SGD","LU0417517546.SGD","HK0000304805.HKD","LU1935043536.SGD","LU1989771016.USD","IE0002141913.USD","LU1923622614.USD","BK4578","SGXZ99366536.SGD","LU0215105999.USD","IE00BFXG0V08.USD","09366","LU0323240290.USD","LU0354030438.USD","LU0942090050.USD","AIFD","LU1791710400.SGD","IE0009355771.USD","LU1548497426.USD","JGRO","LU0661504455.SGD","LU1823568750.SGD","LU0106261372.USD","LU0820561909.HKD","ADBG","LU1880398471.USD","LU1935042488.USD","LU2237957902.USD","LU2065170008.USD","LU0640476718.USD","TSYY","IE00BYQQ9H92.USD","LU0868494617.USD","LU0795875169.SGD","LU1323610961.USD","LU2357305700.SGD","LU0348723411.USD","LU0823414551.USD","LU1699723380.USD","LU2244417387.USD","LU0390134368.USD","LU0823421333.USD","07788","LU0256863811.USD","LU0476273544.USD","SGXZ81514606.USD","SG9999015952.SGD","HK0000819398.USD","WATS","BK4612","NVDD","BK4533","IE00B4YYXB79.USD","LU0138981039.USD","LU0306806265.USD","NVC","LU0466842654.USD","BK4588","IE0034235303.USD","LU0053666078.USD","LU1815336760.USD","LU2125909759.SGD","IE00B3S45H60.SGD","LU2210150020.SGD","LU0342679015.USD","07366","LU1267930730.SGD","LU2462591350.SGD","WANT","LU0310799852.SGD","LU0882574139.USD","IE000W1ABFV2.USD","LU0965508806.USD","LU2089985449.USD","LU1989772840.SGD","BK4511","LU0203201768.USD","LU2360106780.USD","IE00BJT1NW94.SGD","LU2394011477.USD","IE0001KFT4U8.USD","IE00B19Z8X17.USD","LU0107464264.USD","TSDD","EFIV","WISE","LU0912757837.SGD","LU0080751232.USD","LU0289960550.SGD","LU0792757196.USD","LU0256863902.USD","LU2896262040.SGD","BK4141","TSLG","NVIW.SI","IE0004091025.USD","BMY","BK4532","LU2290526834.HKD","LU1551013342.USD","ADBU","SG9999002224.SGD","SG9999018857.SGD","IE000KEQY171.SGD","LU0786609619.USD","LU2322448957.HKD","LU0225771236.USD","LU2756315664.SGD","LU1670711040.USD","BK4592","09388","LU0187121727.USD","TESL","LU1803068979.SGD","IE00B7KXQ091.USD","LU1244550577.SGD","LU1979441026.SGD","TSLZ","LU1923622291.USD","LU0345770308.USD","LU2272731600.USD","LU0289961442.SGD","LU0345769128.USD","SGXZ23171101.USD","LU2463028550.USD","LU2023250504.SGD","BK4555","SG9999014559.SGD","TTXU","LU1951198990.SGD","IE00BMPRXR70.SGD","LU2242646821.SGD","TSLO","TSLT","BK4528","LU1670710588.SGD","NVDY","LU1670710661.SGD","USD","BK4587","LU0353189680.USD","LU0965509101.SGD","NVII","LU2473716301.USD","LU1989764748.USD","LU1642822529.SGD","LU2237443622.USD","LU0072462426.USD","LU1732799900.SGD","LU0237698245.USD","LU1316542783.SGD","LU2265009873.SGD","LU1242518857.USD","LU0787776722.HKD","LU2237957811.SGD","LU0061474960.USD","SNVD.UK","LU0347712357.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664012018","title":"Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2664012018","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664012018?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:35","pubTimestamp":1788467700,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily GainsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  advanced 1.08% to $151.22 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 1.06% to 7,747.71 and the Dow Jones Industrial Average  rising 1.18% to 53,686.11.Gilead Sciences Inc. closed 3.86% short of its 52-week high of $157.29, which the company reached on February 11th.The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Johnson & Johnson  rose 1.17% to $278.43, Pfizer Inc.  fell 0.72% to $28.81, and Abbott Laboratories  fell 1.52% to $108.79.Trading volume  remained 2.3 million below its 50-day average volume of 6.8 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 3, 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","LU1674673691.USD","IE0002270589.USD","LU1037948897.HKD","GILD","BK4566","LU0109394709.USD","LU0859254822.USD","BK4139","IE00B7SZLL34.SGD","LU0823416689.USD","LU0861579265.USD","BIB","BK4585","IBBQ","LU0965509283.SGD","LU1023059063.AUD","LU1066051498.USD","LU0965508806.USD","LU1585245621.USD","LU0058720904.USD","BK4550","LU0965509101.SGD","LU2089984988.USD","IE00B3T34201.USD","LU0234570918.USD","IE00BKVL7J92.USD","IE00B19Z3581.USD","LU2112291526.USD","LU1061106388.HKD","LU2324357040.USD","LU2357627491.SGD","BK4568","IBB","LU0889565916.HKD","LU1037948541.HKD","SG9999015986.USD","BBH","LU1839511570.USD","SG9999015978.USD","LU2087621335.USD","LU0122379950.USD","MEDI","LU0114720955.EUR","LU0289739699.SGD","LU1571399168.USD","LU2468319806.SGD","SG9999015945.SGD","BK4583","LU0965509010.AUD","LU1778281490.HKD","BK4588","LU1934455194.USD","BK4578","LU1430594728.SGD","LU0882574055.USD","LU1934455863.HKD","TBXU","BK4532","LU1066053197.SGD","SG9999015952.SGD","TMED","LU1934455277.USD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","LU1057294990.SGD","LU0320765992.SGD","IE00B19Z3B42.SGD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664499688","title":"Gilead CEO Daniel O'Day Disposes of USD 2.23 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2664499688","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664499688?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:13","pubTimestamp":1788380002,"startTime":"0","endTime":"0","summary":"Gilead CEO Daniel O'Day disposes of USD 2.23 million in common sharesGilead Sciences Chairman and CEO Daniel Patrick O’Day sold 14,000 common shares on Sep. 1, 2026.Sales priced at about $147.51 to $1","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL5HTC5L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gilead CEO Daniel O'Day Disposes of USD 2.23 Million in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","BK4585","LU0965509283.SGD","LU1057294990.SGD","LU0965509101.SGD","IBBQ","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1571399168.USD","LU1674673691.USD","BK4583","TMED","GILD","IE00BZ1G4Q59.USD","LU0965509010.AUD","LU1066051498.USD","LU1839511570.USD","IE0002270589.USD","LU1934455277.USD","LU2357627491.SGD","TBXU","LU0289739699.SGD","LU0882574055.USD","BK4578","LU1066053197.SGD","SG9999015978.USD","LU1934455194.USD","LU1585245621.USD","IE00B7SZLL34.SGD","LU0114720955.EUR","IBB","LU0122379950.USD","LU0861579265.USD","LU1061106388.HKD","LU0823416689.USD","LU2087621335.USD","LU0889565916.HKD","BIB","LU2324357040.USD","IE00BSNM7G36.USD","SG9999015952.SGD","LU0320765992.SGD","LU0965508806.USD","LU0058720904.USD","MEDI","LU1023059063.AUD","LU0109394709.USD","BMED","BK4568","LU0859254822.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664843956","title":"H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme","url":"https://stock-news.laohu8.com/highlight/detail?id=2664843956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664843956?lang=en_us&edition=fundamental","pubTime":"2026-09-03 00:40","pubTimestamp":1788367217,"startTime":"0","endTime":"0","summary":"H.C. Wainwright reiterates a Buy rating on Halozyme (HALO) with a $115 price target after Novartis (NVS) signed an option and license agreement wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-views-novartis-alteogen-pact-as-negative-for-halozyme-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-views-novartis-alteogen-pact-as-negative-for-halozyme-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4588","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4139","BK4007","IE0002141913.USD","IE00BJT1NW94.SGD","BK4585","IE00BJJMRZ35.SGD","LU0211331839.USD","LU0208291251.USD","BK4578","FFOX","IE0009355771.USD","PPH","IE00BFTCPJ56.SGD","NVS","HALO","LU0320765489.SGD","MEDX","LU0053671581.USD","LU0070302665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664848720","title":"Novartis AG Rises Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2664848720","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664848720?lang=en_us&edition=fundamental","pubTime":"2026-09-03 00:15","pubTimestamp":1788365700,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novartis AG  advanced 0.3% to CHF131.32 Wednesday on what proved to be an overall favorable trading session for the stock market, with the Swiss Market Index SMI Index  rising 0.2% to 14,362.97.Novartis AG closed CHF1.16 below its 52-week high of CHF132.48, which the company achieved on September 1, 2026.Trading volume was 3,637,896, compared to the 50-day average trading volume of 2,304,599.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4007","IE0002141913.USD","IE00BJT1NW94.SGD","BK4585","IE00BJJMRZ35.SGD","LU0211331839.USD","LU0208291251.USD","BK4578","IE0009355771.USD","PPH","IE00BFTCPJ56.SGD","NVS","LU0320765489.SGD","MEDX","LU0070302665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664162238","title":"Novartis, Alteogen Sign Drug-Technology Deal Worth Up to $3.2 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2664162238","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664162238?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:35","pubTimestamp":1788348951,"startTime":"0","endTime":"0","summary":"Novartis  has signed an option and licensing agreement with South Korean biotech Alteogen to develop and sell subcutaneous versions of multiple Novartis drugs using its ALT-B4 technology, Alteogen said Wednesday.The company said ALT-B4 is designed to convert biologic medicines typically given through intravenous infusions into faster injections under the skin.If Novartis exercises all options and all milestones are met, Alteogen could receive up to $3.223 billion, including option fees, development and commercial milestones, and royalties on product sales, it added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PPH","LU0208291251.USD","BK4532","LU0070302665.USD","LU0211331839.USD","BK4585","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4588","IE00BJJMRZ35.SGD","BK4007","MEDX","IE00B2B36J28.USD","IE0009355771.USD","LU0320765489.SGD","BK4578","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664381433","title":"Is Gilead Sciences (GILD) Fully Valued On Its New HIV And Cancer Drug Approvals?","url":"https://stock-news.laohu8.com/highlight/detail?id=2664381433","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664381433?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:23","pubTimestamp":1788348209,"startTime":"0","endTime":"0","summary":"Gilead Sciences (GILD) has drawn fresh investor attention after two recent regulatory decisions. The FDA approved Bixlenvo for virologically suppressed adults with HIV, and the European Commission cleared Trodelvy plus Keytruda for certain metastatic triple-negative breast cancer patients.\nThese approvals arrive after a strong run in Gilead Sciences' stock, with a 30-day share price return of 15.14% and a year-to-date share price return of 23.29%, alongside a 36.48% 1-year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/is-gilead-sciences-gild-fully-valued-on-its-new-hiv-and-canc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/is-gilead-sciences-gild-fully-valued-on-its-new-hiv-and-canc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0114720955.EUR","LU1066051498.USD","BMED","LU1674673428.USD","LU0889565916.HKD","IBB","BK4585","LU0965509283.SGD","SG9999015986.USD","MEDI","LU0109394709.USD","BK4139","LU0965509101.SGD","IE0002270589.USD","LU1934455194.USD","BK4566","SG9999015952.SGD","SG9999015978.USD","LU1585245621.USD","LU1778281490.HKD","IE00B3T34201.USD","LU2089984988.USD","LU1023059063.AUD","IBBQ","BIB","LU0823416689.USD","LU1037948541.HKD","LU2324357040.USD","GILD","TBXU","BBH","IE00B19Z3581.USD","LU1061106388.HKD","BK4532","LU2112291526.USD","TMED","LU0122379950.USD","LU1066053197.SGD","IE00BZ1G4Q59.USD","LU1934455863.HKD","LU0289739699.SGD","LU1674673691.USD","LU0882574055.USD","IE00B7SZLL34.SGD","LU0859254822.USD","LU2087621335.USD","LU0058720904.USD","BK4588","BK4578","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664165388","title":"Alteogen enters option, license agreement with Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2664165388","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664165388?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:15","pubTimestamp":1788347740,"startTime":"0","endTime":"0","summary":"Alteogen announced that it has entered into an option and license agreement with Novartis (NVS) for the development and commercialization of subcut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alteogen-enters-option-license-agreement-with-novartis-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alteogen-enters-option-license-agreement-with-novartis-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPH","LU0208291251.USD","BK4532","LU0070302665.USD","LU0211331839.USD","BK4585","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4588","IE00BJJMRZ35.SGD","BK4007","MEDX","IE00B2B36J28.USD","IE0009355771.USD","LU0320765489.SGD","BK4578","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664920892","title":"Novartis Trial Suspensions to Have Limited Financial Impact","url":"https://stock-news.laohu8.com/highlight/detail?id=2664920892","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664920892?lang=en_us&edition=fundamental","pubTime":"2026-09-02 16:15","pubTimestamp":1788336900,"startTime":"0","endTime":"0","summary":"0815 GMT - Novartis's decision to suspend several clinical trials for a cell therapy after three patients died is expected to have a limited financial impact, Citi analysts say in a research note. Pending further updates, the news reduces the likelihood that the Swiss drugmaker's next-generation cell-therapy platform--which aims to accelerate the process of T-cell expansion to treat autoimmune diseases--could provide a future boost, the analysts say. However, the treatment was still in midstage trials, and Citi's current peak sales estimate stands at only $440 million. Novartis shares fall 0.6%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","BK4578","IE00BJT1NW94.SGD","LU0208291251.USD","BK4007","LU0070302665.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4532","PPH","MEDX","BK4585","LU0211331839.USD","BK4588","IE00B2B36J28.USD","LU0320765489.SGD","IE0009355771.USD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664999869","title":"Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2664999869","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664999869?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:35","pubTimestamp":1788294900,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  rallied 2.45% to $149.92 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index  falling 0.71% to 7,631.47 and Dow Jones Industrial Average  falling 0.79% to 52,766.88.This was the stock's second consecutive day of gains.Gilead Sciences Inc. closed 4.69% short of its 52-week high of $157.29, which the company reached on February 11th.The stock outperformed some of its competitors Tuesday, as Johnson & Johnson  rose 2.01% to $271.19, Pfizer Inc.  rose 0.32% to $28.55, and Abbott Laboratories  fell 1.30% to $108.93.Trading volume  remained 2.1 million below its 50-day average volume of 6.9 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 1, 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","LU1778281490.HKD","LU0889565916.HKD","TMED","LU1839511570.USD","LU1585245621.USD","LU1061106388.HKD","BMED","LU0859254822.USD","BK4583","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU0109394709.USD","IBBQ","LU2324357040.USD","LU2089984988.USD","BK4588","BIB","BK4585","IBB","LU1674673691.USD","LU2087621335.USD","LU2112291526.USD","BK4568","SG9999015952.SGD","LU0882574055.USD","BK4566","SG9999015945.SGD","LU0114720955.EUR","BK4139","LU1066053197.SGD","LU1934455194.USD","LU0289739699.SGD","TBXU","LU1571399168.USD","LU1674673428.USD","IE00B19Z3581.USD","LU0965509010.AUD","LU0965508806.USD","LU0965509283.SGD","IE00BZ1G4Q59.USD","LU2468319806.SGD","LU0823416689.USD","LU1430594728.SGD","IE00BSNM7G36.USD","BK4532","LU0234570918.USD","LU0861579265.USD","LU0965509101.SGD","GILD","LU0320765992.SGD","LU1057294990.SGD","SG9999015978.USD","SG9999015986.USD","LU1037948897.HKD","LU1023059063.AUD","LU1066051498.USD","IE00B19Z3B42.SGD","BK4578","LU0122379950.USD","LU1934455277.USD","IE00B3T34201.USD","LU0058720904.USD","LU2357627491.SGD","MEDI","LU1934455863.HKD","BK4550","BBH","LU1037948541.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":106,"code":"91000000","status":"200"}]}}